Domainex makes a breakthrough on novel protein-protein interaction cancer target

February 2010

Our scientists have been instrumental in identifying small-molecule inhibitors of the Neuropilin 1 – VEGF-A interaction, thereby demonstrating that this is an important target for the development of novel anticancer therapeutics. The work, reported in the latest edition of the Journal of Medicinal Chemistry, was carried out by Domainex on behalf of its client Ark Therapeutics. Protein-protein interactions have for a long time been considered tough targets for small-molecule drug discovery, but Domainex has demonstrated that its approach, based on high-quality structure based drug design and insightful medicinal chemistry, is able to crack even difficult problems such as these.